< Back to situations

[ORGANIZATION]

H. C. Wainwright

Featured in 5 tracked stories · first seen

Situations

[QUIET] [BUSINESS] [CH]

Novartis remibrutinib Phase III clinical trial results

2 clusters · 14 sources · last updated

Latest: Novartis reports positive Phase III results for oral MS drug remibrutinib

Novartis has reported positive topline results from two Phase III clinical trials, REMODEL-1 and REMODEL-2, evaluating its experimental oral drug remibrutinib for the treatment of relapsing multiple sclerosis. The drug,

[QUIET] [BUSINESS] [US] [CA] [HK]

2 clusters · 4 sources · last updated

Latest: SBC Medical announces September 2026 investor conference schedule

[QUIET] [BUSINESS] [US] [GB]

Orchestra BioMed corporate developments

2 clusters · 4 sources · last updated

Latest: Orchestra BioMed and Immunocore announce investor conference appearances

Orchestra BioMed Holdings, Inc. has moved from reporting financial forecasts and insider trading activity toward presenting its clinical developments at investor conferences. In early August, the company prepared to rel

Also covered in